PL3851537T3 - Leczenie hiperbilirubinemii - Google Patents

Leczenie hiperbilirubinemii

Info

Publication number
PL3851537T3
PL3851537T3 PL21151019.3T PL21151019T PL3851537T3 PL 3851537 T3 PL3851537 T3 PL 3851537T3 PL 21151019 T PL21151019 T PL 21151019T PL 3851537 T3 PL3851537 T3 PL 3851537T3
Authority
PL
Poland
Prior art keywords
hyperbilirubinemia
treatment
Prior art date
Application number
PL21151019.3T
Other languages
English (en)
Inventor
Federico Mingozzi
Giuseppe RONZITTI
Fanny COLLAUD
Andrés MURO
Giulia BORTOLUSSI
Original Assignee
Genethon
International Centre For Genetic Engineering And Biotechnology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genethon, International Centre For Genetic Engineering And Biotechnology filed Critical Genethon
Publication of PL3851537T3 publication Critical patent/PL3851537T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1051—Hexosyltransferases (2.4.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/01—Hexosyltransferases (2.4.1)
    • C12Y204/01017—Glucuronosyltransferase (2.4.1.17)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL21151019.3T 2014-04-25 2015-04-27 Leczenie hiperbilirubinemii PL3851537T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14305622 2014-04-25
EP14196400 2014-12-04

Publications (1)

Publication Number Publication Date
PL3851537T3 true PL3851537T3 (pl) 2024-09-16

Family

ID=53039406

Family Applications (2)

Application Number Title Priority Date Filing Date
PL21151019.3T PL3851537T3 (pl) 2014-04-25 2015-04-27 Leczenie hiperbilirubinemii
PL19172023.4T PL3546585T3 (pl) 2014-04-25 2015-04-27 Kwasy nukleinowe zawierające zmodyfikowany intron do zastosowania w leczeniu hiperbilirubinemii

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL19172023.4T PL3546585T3 (pl) 2014-04-25 2015-04-27 Kwasy nukleinowe zawierające zmodyfikowany intron do zastosowania w leczeniu hiperbilirubinemii

Country Status (11)

Country Link
US (3) US10471132B2 (pl)
EP (4) EP3546585B1 (pl)
JP (3) JP6730193B2 (pl)
CN (2) CN114395559A (pl)
AU (1) AU2015250770B2 (pl)
CA (2) CA2942451C (pl)
DK (3) DK3134530T3 (pl)
ES (3) ES2744565T3 (pl)
FI (2) FI3851537T3 (pl)
PL (2) PL3851537T3 (pl)
WO (1) WO2015162302A2 (pl)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010045659A1 (en) 2008-10-17 2010-04-22 American Gene Technologies International Inc. Safe lentiviral vectors for targeted delivery of multiple therapeutic molecules
GB201420139D0 (en) 2014-11-12 2014-12-24 Ucl Business Plc Factor IX gene therapy
GB201508026D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Capsid
US11980663B2 (en) 2015-07-08 2024-05-14 American Gene Technologies International Inc. HIV pre-immunization and immunotherapy
US20190307857A1 (en) * 2015-12-09 2019-10-10 Modernatx, Inc. MODIFIED mRNA ENCODING A URIDINE DIPHOPSPHATE GLUCURONOSYL TRANSFERASE AND USES THEREOF
AU2016370590B2 (en) * 2015-12-14 2023-11-02 The Trustees Of The University Of Pennsylvania Composition for treatment of Crigler-Najjar syndrome
EP3393522B1 (en) * 2015-12-22 2021-07-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Improved hybrid dual recombinant aav vector systems for gene therapy
IL297238B2 (en) 2016-01-15 2024-08-01 American Gene Tech Int Inc Methods and preparations for gamma-delta T-cell activation
US10137144B2 (en) 2016-01-15 2018-11-27 American Gene Technologies International Inc. Methods and compositions for the activation of gamma-delta T-cells
JP7153332B2 (ja) 2016-02-08 2022-10-14 アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド Ｈｉｖワクチン接種および免疫療法
ES2911448T3 (es) 2016-03-09 2022-05-19 American Gene Tech Int Inc Vectores combinados y métodos para el tratamiento del cáncer
CN105721252B (zh) * 2016-03-24 2020-09-25 腾讯科技（深圳）有限公司 数据包乱序度的测量方法和系统
GB201608046D0 (en) * 2016-05-09 2016-06-22 Cambridge Entpr Ltd And Syndey Children S Hospitals Network Randwick And Westmead Incorporating The Treatment of complement-mediated disorders
WO2017213697A1 (en) 2016-06-08 2017-12-14 American Gene Technologies International Inc. Non-integrating viral delivery system and methods related thereto
CA3028982A1 (en) 2016-07-08 2018-01-11 American Gene Technologies International Inc. Hiv pre-immunization and immunotherapy
WO2018017882A1 (en) 2016-07-21 2018-01-25 American Gene Technologies International Inc. Viral vectors for treating parkinson's disease
EP3293260A1 (en) 2016-09-12 2018-03-14 Genethon Acid-alpha glucosidase variants and uses thereof
EP3293203A1 (en) 2016-09-12 2018-03-14 Genethon Acid-alpha glucosidase variants and uses thereof
EP3293259A1 (en) 2016-09-12 2018-03-14 Genethon Acid-alpha glucosidase variants and uses thereof
KR102617502B1 (ko) 2016-09-12 2023-12-26 제네똥 산-알파 글루코시다제 변이체 및 이의 용도
MA47820A (fr) 2017-03-10 2020-01-15 Genethon Traitement de la glycogénose de type iii
US11820999B2 (en) 2017-04-03 2023-11-21 American Gene Technologies International Inc. Compositions and methods for treating phenylketonuria
US12559769B2 (en) 2017-06-16 2026-02-24 American Gene Technologies International Inc. Methods and compositions for the activation of tumor cytotoxicity via human gamma-delta t-cells
PL3648783T3 (pl) * 2017-07-07 2024-11-18 Genethon Nowe polinukleotydy kodujące ludzkie białko fkrp
KR20200057766A (ko) * 2017-10-02 2020-05-26 아메리칸 진 테크놀로지스 인터내셔널 인코포레이티드 페닐케톤뇨증을 치료하기 위한 프로모터 및 인핸서 조합을 포함하는 벡터
CA3086942A1 (en) 2018-02-07 2019-08-15 Genethon Hybrid regulatory elements
JP7142815B2 (ja) * 2018-06-21 2022-09-28 株式会社遺伝子治療研究所 ヒト肝臓への遺伝子導入のためのアデノ随伴ウイルスビリオン
CN109082402B (zh) * 2018-08-06 2021-08-17 复旦大学 一种aav-dj型腺相关病毒体外高效感染类器官的用途
CA3107572A1 (en) 2018-08-08 2020-02-13 Genethon Mini-gde for the treatment of glycogen storage disease iii
GB201813528D0 (en) 2018-08-20 2018-10-03 Ucl Business Plc Factor IX encoding nucleotides
US10842885B2 (en) 2018-08-20 2020-11-24 Ucl Business Ltd Factor IX encoding nucleotides
AU2019359276A1 (en) * 2018-10-09 2021-04-29 The University Of North Carolina At Chapel Hill Regulated gene editing system
US20220042045A1 (en) * 2018-12-21 2022-02-10 Genethon Expression cassettes for gene therapy vectors
CN113795575A (zh) 2019-02-04 2021-12-14 自由行疗法有限公司 多核苷酸
EP3956354A1 (en) * 2019-04-19 2022-02-23 Genethon Gene therapy of fibroblast growth factor 23 related hypophosphatemic diseases
JP7853100B2 (ja) * 2019-06-05 2026-04-28 オーチャード セラピューティクス（ヨーロッパ）リミテッド 真核細胞を修飾するための組成物及び方法
IT201900008877A1 (it) * 2019-06-13 2020-12-13 Univ Bologna Alma Mater Studiorum Nuovi costrutti per terapia genica
US12662512B2 (en) 2019-10-22 2026-06-23 Genethon Chimeric polypeptides and uses thereof
WO2021078834A1 (en) 2019-10-22 2021-04-29 Genethon Chimeric acid-alpha glucosidase polypeptides and uses thereof
EP3913060A1 (en) 2020-05-22 2021-11-24 Genethon Vectors encoding a glucose-6-phosphatase (g6pase-a) for gene therapy
JP2023539219A (ja) 2020-08-24 2023-09-13 ジェネトン 糖原病ｉｉｉの治療のためのｃ末端切断ｇｄｅ
US20230374542A1 (en) 2020-10-07 2023-11-23 Asklepios Biopharmaceutical, Inc. Therapeutic adeno-associated virus delivery of fukutin related protein (fkrp) for treating dystroglycanopathy. disorders including limb girdle 21 (lgmd21)
WO2022177597A1 (en) * 2021-02-16 2022-08-25 The Board Of Trustees Of The Leland Stanford Junior University Systems and methods to enhance rna stability and translation and uses thereof
WO2023237731A1 (en) 2022-06-09 2023-12-14 Genethon N-terminal truncated gde for the treatment of glycogen storage disease iii
WO2025003477A1 (en) 2023-06-29 2025-01-02 Genethon N-terminal truncated glycogen debranching enzymes for the treatment of glycogen storage disease iii

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2063799A1 (en) * 1989-07-24 1991-01-25 Frank S. Genbauffe Prevention of internal initiation
AU1333797A (en) * 1995-12-15 1997-07-03 Systemix, Inc. Method for obtaining retroviral vector supernatant having high transduction efficiency
US5910434A (en) * 1995-12-15 1999-06-08 Systemix, Inc. Method for obtaining retroviral packaging cell lines producing high transducing efficiency retroviral supernatant
CN1247785C (zh) * 2000-10-13 2006-03-29 希龙公司 巨细胞病毒内含子a片段
ES2932278T3 (es) 2004-06-01 2023-01-17 Genzyme Corp Composiciones y métodos para prevenir la agregación del vector AAV
WO2006102643A2 (en) * 2005-03-24 2006-09-28 Caritas St. Elizabeth Medical Center Boston, Inc. Stably transformed bone marrow-derived cells and uses thereof
AU2006242371A1 (en) 2005-04-29 2006-11-09 The University Of North Carolina At Chapel Hill Methods and compositions for regulated expression of nucleic acid at post-transcriptional level
WO2007120533A2 (en) * 2006-03-30 2007-10-25 The Board Of Trustees Of The Leland Stanford Junior University Minigene expression cassette
KR101229418B1 (ko) 2007-06-15 2013-02-05 재단법인 목암생명공학연구소 활성형 재조합 혈액응고 9인자의 대량생산 방법
EP2014301A1 (en) * 2007-07-13 2009-01-14 TopoTarget Germany AG Optimized DNA and protein sequence of an antibody to improve quality and yield of bacterially expressed antibody fusion proteins
CN101348786B (zh) * 2007-07-20 2011-05-11 谭孟群 一种人β珠蛋白基因及其重组腺相关病毒载体
KR20110086553A (ko) * 2008-09-29 2011-07-28 암스테르담 몰레큘러 테라퓨틱스 비. 브이. 포르포빌리노겐 디아미나아제 유전자 치료
CN101671740B (zh) * 2009-10-19 2012-05-23 广州益善生物技术有限公司 Ugt1a1基因多态性检测的方法及液相芯片
CN102791877A (zh) * 2009-11-06 2012-11-21 酶学有限公司 使用双链核酸复合物与耐热聚合酶用于合成脱氧核糖核苷酸链的组合物和方法
ES2618899T3 (es) 2010-02-26 2017-06-22 The Children's Hospital Of Philadelphia Zimógeno de proteína C y procedimientos de utilización del mismo para prevenir las metástasis del cáncer
CN110777124A (zh) 2011-10-27 2020-02-11 威尔斯达眼科制剂公司 编码视杆细胞来源的视锥细胞活力因子的载体
CN102643906A (zh) * 2012-04-01 2012-08-22 周宏灏 焦磷酸测序法检测伊立替康个体化用药基因多态性的试剂盒及方法
CN104411338A (zh) * 2012-04-02 2015-03-11 现代治疗公司 用于产生与人类疾病相关的生物制剂和蛋白质的修饰多核苷酸
WO2014014122A1 (en) * 2012-07-16 2014-01-23 Kyoto University Translational control system using rna-protein interaction motif
US9555094B2 (en) * 2012-07-23 2017-01-31 The Institute Of Biological Resources Isolated nucleic acid for the production of a vaccine against virus
CN103146804B (zh) * 2013-02-04 2015-04-22 中国科学院大连化学物理研究所 葡萄糖醛酸转移酶ugt1a1的特异性探针底物及应用
NZ716102A (en) 2013-07-22 2021-12-24 The Children’S Hospital Of Philadelphia Variant aav and compositions, methods and uses for gene transfer to cells, organs and tissues
CN104789532B (zh) * 2015-03-30 2019-06-11 汉恒生物科技（上海）有限公司 一种表达腺病毒的细胞株及高效制备腺病毒的方法

Also Published As

Publication number Publication date
CA3205555A1 (en) 2015-10-29
US10471132B2 (en) 2019-11-12
AU2015250770B2 (en) 2020-10-01
JP2022088645A (ja) 2022-06-14
FI3851537T3 (fi) 2024-03-21
JP6730193B2 (ja) 2020-07-29
EP3851537B1 (en) 2023-12-27
JP7349931B2 (ja) 2023-09-25
DK3851537T3 (da) 2024-03-18
CN114395559A (zh) 2022-04-26
EP3851537A1 (en) 2021-07-21
ES2971434T3 (es) 2024-06-05
DK3851537T5 (da) 2024-08-19
JP2020103300A (ja) 2020-07-09
EP4643946A3 (en) 2026-03-04
EP3546585B1 (en) 2025-09-10
US20230414724A1 (en) 2023-12-28
WO2015162302A3 (en) 2015-12-30
CN106459932B (zh) 2022-01-11
CN106459932A (zh) 2017-02-22
US20190374619A1 (en) 2019-12-12
US20170028036A1 (en) 2017-02-02
JP2017513501A (ja) 2017-06-01
CA2942451A1 (en) 2015-10-29
WO2015162302A2 (en) 2015-10-29
ES2744565T3 (es) 2020-02-25
ES3050307T3 (en) 2025-12-19
EP3134530A2 (en) 2017-03-01
EP3134530B1 (en) 2019-06-12
AU2015250770A1 (en) 2016-09-29
EP4643946A2 (en) 2025-11-05
PL3546585T3 (pl) 2026-05-18
DK3546585T3 (da) 2025-11-03
EP3546585A1 (en) 2019-10-02
FI3546585T3 (fi) 2025-11-20
CA2942451C (en) 2024-09-10
DK3134530T3 (da) 2019-09-09

Similar Documents

Publication Publication Date Title
IL252839A0 (en) Treatment of boils
GB201701673D0 (en) Methods of well treatment
IL250677A0 (en) Cancer treatment using anti-nkg2a agents
PT3212233T (pt) Terapia combinada para o tratamento de doenças
SMT202100115T1 (it) Combinazioni di inibitori di fgfr e cmet per il trattamento del cancro
IL248856B (en) New treatment
IL246880A0 (en) Tumor treatment
GB201416832D0 (en) Methods of treatment
GB201408297D0 (en) Treatment of cancer
GB201410407D0 (en) Treatment of chagas disease
GB201412010D0 (en) Treatment of hypertransaminasemia
GB201417456D0 (en) Treatment of cancer
GB201512139D0 (en) Methods of treatment
PT3851537T (pt) Tratamento da hiperbilirrubinemia
GB201409362D0 (en) Treatment of cancer
GB201405449D0 (en) Treatment of cancer
GB201405075D0 (en) Treatment of cancer
GB201417465D0 (en) Treatment of cancers
GB201512723D0 (en) Treatment of cancer
GB201507928D0 (en) Treatment of cancer
GB201504617D0 (en) Treatment of cancer
GB201412285D0 (en) Therapeutic treatments
GB201412293D0 (en) Therapeutic treatments
GB201417719D0 (en) New treatment
GB201408384D0 (en) New treatment